A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Colon Cancer|Rectal Cancer|Neoplasms|Endometrial Cancer|Soft Tissue Sarcoma|Triple Negative Breast Cancer|Pancreas Cancer|Pancreatic Cancer
Interventions: DRUG: LY2880070|DRUG: Gemcitabine
Sponsor: Esperas Pharma Inc.